2019
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy
Zammataro L, Lopez S, Bellone S, Pettinella F, Bonazzoli E, Perrone E, Zhao S, Menderes G, Altwerger G, Han C, Zeybek B, Bianchi A, Manzano A, Manara P, Cocco E, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Angioli R, Raspagliesi F, Scambia G, Choi J, Dong W, Bilguvar K, Alexandrov LB, Silasi DA, Huang GS, Ratner E, Azodi M, Schwartz PE, Pirazzoli V, Stiegler AL, Boggon TJ, Lifton RP, Schlessinger J, Santin AD. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 22730-22736. PMID: 31624127, PMCID: PMC6842590, DOI: 10.1073/pnas.1911385116.Peer-Reviewed Original ResearchConceptsPI3K/AKT/mTOR pathwaySquamous cell carcinomaWhole-exome sequencingAKT/mTOR pathwayPrimary cervical cancer cell linesPIK3CA inhibitorsRecurrent cervical cancer patientsMTOR pathwayCombination of copanlisibCervical cancer patientsPI3K/Akt/mTORCervical cancer xenograftsRegression of tumorsCervical cancer cell linesCervical tumor cell linesSingle nucleotide variantsWild-type tumorsRecurrent somatic missense mutationsAkt/mTORCell linesPan-HERCancer cell linesTypes 16/18Cervical cancerCancer patients
2014
KRAS mutation testing in clinical practice
Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2014, 15: 375-384. PMID: 25487540, DOI: 10.1586/14737159.2015.986102.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKRAS mutation testingKRAS mutationsMetastatic colorectal carcinomaLung cancer patientsMutations of KRASCommon human malignanciesMutation testingCombinatorial therapeutic strategiesCancer patientsColorectal carcinomaThyroid cancerClinical aggressivenessClinical OncologyTherapeutic strategiesClinical practiceMolecular testingCytological specimensHuman malignanciesPrecision medicinePatientsCancerEssential biomarkersDownstream effectorsCurrent practiceMutations
2012
Demographics of uterine serous cancer (USC) patients: A single institutional experience.
de Leon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Demographics of uterine serous cancer (USC) patients: A single institutional experience. Journal Of Clinical Oncology 2012, 30: e15581-e15581. DOI: 10.1200/jco.2012.30.15_suppl.e15581.Peer-Reviewed Original ResearchPast medical historyUterine cancerUSC patientsSEER dataBreast cancerPrior historyLargest single-institution experienceCommon uterine cancerSerous cancer patientsSmall institutional seriesSingle institution experienceSingle institutional experienceForms of cancerOlder ptsPt ageDiabetic womenPostmenopausal womenFIGO stageInstitutional seriesOral contraceptivesMenopause statusCancer patientsDisease stageMedical historyEstrogen dependency